
    
      A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study
      to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different
      doses and regimens of GW873140 in combination with Kaletra (lopinavir and ritonavir) in HIV-1
      infected antiretroviral therapy naive subjects
    
  